ORION CORPORATION PRESS RELEASE 20 JUNE 2025 at 13.30 EEST CHMP recommends third indication for darolutamide for patients ...

Berlin: Bayer has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

EMA committee recommends marketing approval for Bayer’s Nubeqa for patients with advanced prostate cancer: Berlin Saturday, June 21, 2025, 10:00 Hrs [IST] The Committee for Medi ...

A review of 22 trials led the American Society of Clinical Oncology (ASCO) to issue updates to its mCRPC systemic therapy ...

ORION CORPORATION PRESS RELEASE 20 JUNE 2025 at 13.30 EEST CHMP recommends third indication for darolutamide for patients with advanced prostate cancer CHMP adopts positive opinion for the ...

Androgen deprivation therapy (ADT) for men with prostate cancer, whether induced by bilateral orchiectomy or by gonadotropin-releasing hormone agonists, can result in a 2–10-fold increase in ...

However, among patients who did not receive androgen-deprivation therapy, hypofractionated radiotherapy halved the risk for treatment failure. The initial findings from the phase III randomized ...

An expert discusses how combining androgen receptor pathway inhibitors (ARPIs) with PARP inhibitors, particularly ...

Pfizer Inc. (NYSE:PFE) has unveiled major advances in cancer research at the 2025 ASCO Annual Meeting, spotlighting robust five-year survival results for XTANDI (enzalutamide) combined with androgen ...